SWITZERLAND – Nestlé Health Science has launched Celltrient Cellular Energy, a protein-based flavored drink mix to help renew natural processes that decline as one ages.
Celltrient Cellular Energy contains ChromaDex’s flagship ingredient, Tru Niagen (nicotinamide riboside). While traditional micro and macronutrients may satisfy one’s basic dietary needs and are readily available through food, those nutrients may not suffice to combat the age-related decline in NAD+ (nicotinamide adenine dinucleotide) levels.
The formulation also provides sources of Vitamin C and additional B vitamins (B12, B5, B6, Riboflavin, Thiamin & Biotin) to support energy metabolism.
ChromaDex and Nestlé Health Science entered a global commercial license and supply agreement for Tru Niagen within the medical nutrition and consumer health categories in December 2018, and Celltrient Energy is the first product launched from this partnership.
“We are pleased to see the Nestlé Health Science launch of Celltrient Cellular Energy. Tru Niagen, the only proprietary form of NR, provides healthy aging and energy support at the cellular level by safely and effectively increasing NAD+ levels.”Rob Fried – CEO, ChromaDex
The new product includes a 250mg serving of Tru Niagen (nicotinamide riboside, or NR) and is one of three products under the new Celltrient brand.
“We are pleased to see the Nestlé Health Science launch of Celltrient Cellular Energy. Tru Niagen, the only proprietary form of NR, provides healthy aging and energy support at the cellular level by safely and effectively increasing NAD+ levels,” says ChromaDex CEO Rob Fried.
Supporting cellular defense and repair by boosting NAD+ levels is important for healthy aging. NAD+ levels decline with age as well as physiological stressors including stress on the immune system, intense physical exercise, alcohol consumption, and lack of healthy sleep cycles.
Tru Niagen increases NAD+ levels safely and efficaciously, as demonstrated in multiple published human trials.
“We are proud to be in partnership with the pioneers at ChromaDex who are unveiling the full potential of NAD+ through their research,” says Nestlé Health Science CEO Greg Behar.
Recently, Nestlé Health Science completed the acquisition of Aimmune Therapeutics, Inc., a biopharmaceutical company and a peanut allergy treatment maker, as it expands its fast-growing health science business.
The company which specializes in developing and bringing new treatments to people with potentially life-threatening food allergies joins Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc’s global pharmaceutical business.
Liked this article? Subscribe to Food Business Africa News, our regular email newsletters with the latest news insights from Africa and the World’s food and agro industry. SUBSCRIBE HERE